Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
168 stopped studies mapped to Lung Neuroendocrine Carcinoma and descendants · 92% state a reason
Over the 168 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 25, 2023 | Hansoh BioMedical R&D Company | Research and development strategy adjustment. | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | — | terminated | Apr 17, 2018 | HKGepitherapeutics | Encountered technical issues with blood plasma samples received from the hospital. | Other (stated, no rule matched) |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT03995667 | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung… | Phase 2 | terminated | Jun 24, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT04308785 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small… | Phase 2 | terminated | Mar 16, 2020 | Hoffmann-La Roche | The sponsor's decision was based on the negative results of SKYSCRAPER-02. | Sponsor / business decision |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of… | Phase 2 | withdrawn | Dec 17, 2021 | University of Washington | Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled. | Enrollment / accrual |
| NCT02899728 | Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small… | Phase 2 | terminated | Sep 14, 2016 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03366103 | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and… | Phase 1 / Phase 2 | terminated | Dec 8, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate… | — | terminated | Sep 26, 2019 | Fate Therapeutics | This study was terminated by the Sponsor. | Other (stated, no rule matched) |
| NCT03963414 | A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC | Phase 1 | terminated | May 24, 2019 | University of Nebraska | low accrual | Enrollment / accrual |
| NCT05027867 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | Phase 2 | terminated | Aug 30, 2021 | Kartos Therapeutics, Inc. | Unanticipated and extremely high screen failure rate. There was no evidence of safety concerns in… | Safety / toxicity |
| NCT04750239 | Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell… | Phase 1 / Phase 2 | terminated | Feb 11, 2021 | Y-mAbs Therapeutics | Study terminated due to business priorities | Sponsor / business decision |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell… | Phase 2 | withdrawn | Jun 9, 2022 | Ellipses Pharma | Futility analysis decision to terminate EP0057 compound and all Ellipses sponsored studies… | Efficacy / futility |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch…(REFIT-MSS) | Phase 2 | withdrawn | Oct 17, 2022 | Translational Research in Oncology | Study never started/ will not proceed. | Other (stated, no rule matched) |
| NCT03488472 | Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain(RAD 1704) | N/A | terminated | Apr 5, 2018 | Drexell Hunter Boggs | This feasibility study only accrued one patient since site activation. We believe that the primary… | Enrollment / accrual |
| NCT04590781 | Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or… | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Xencor, Inc. | The study has been terminated early by the sponsor due to business decision. | Sponsor / business decision |
| NCT03406715 | Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With… | Phase 2 | terminated | Jan 23, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor closed study | Other (stated, no rule matched) |
| NCT02963090 | Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | Phase 2 | terminated | Nov 15, 2016 | Alliance Foundation Trials, LLC. | Lack of enrollment | Enrollment / accrual |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung… | Phase 2 | terminated | Dec 24, 2010 | Ludwig Institute for Cancer Research | Lack of efficacy in Cohort 2; slow enrollment in Cohort 1 | Efficacy / futility |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects… | Phase 1 | terminated | Jul 17, 2019 | Aileron Therapeutics, Inc. | With a favorable safety profile the difference between treatment groups for the primary composite… | Safety / toxicity |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung… | Phase 1 / Phase 2 | terminated | Dec 24, 2019 | Ascentage Pharma Group Inc. | Sponsor decision | Sponsor / business decision |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by the IRB 5/26/22 due to non-compliance | Other (stated, no rule matched) |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer… | Phase 3 | terminated | Feb 3, 2006 | Sumitomo Pharma Co., Ltd. | not stated | Not stated |
| NCT04525391 | AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer(SUKSES-N5) | Phase 2 | terminated | Aug 25, 2020 | Se-Hoon Lee | Recommended completion of the study due to SUSAR occurring in other clinical trials conducted with… | Other (stated, no rule matched) |
| NCT02934503 | Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung… | Phase 2 | terminated | Oct 17, 2016 | NYU Langone Health | This study was terminated as the standard of care for small cell lung cancer changed in 2018 to… | Other (stated, no rule matched) |
| NCT04422210 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax… | Phase 1 | terminated | Jun 9, 2020 | Hoffmann-La Roche | Decision to discontinue the study based on broader development and strategic prioritisation. The… | Sponsor / business decision |
| NCT04677361 | Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With… | Early Phase 1 | withdrawn | Dec 21, 2020 | Fox Chase Cancer Center | Grantor shifted focus in disease, funding was stopped | Funding |
| NCT03387332 | APG-1252 in Patients With SCLC or Advanced Solid Tumors | Phase 1 | terminated | Jan 2, 2018 | Ascentage Pharma Group Inc. | The company adjusts strategy. | Sponsor / business decision |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line…(MERU) | Phase 3 | terminated | Jan 26, 2017 | AbbVie | Independent Data Monitoring Committee recommendation | Other (stated, no rule matched) |
| NCT01573338 | Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together… | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Bayer | not stated | Not stated |
| NCT02722369 | STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus… | Phase 2 | terminated | Mar 30, 2016 | University College, London | Low recruitment, lack of efficacy and increased adverse events in investigational arm. | Safety / toxicity |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | Phase 1 / Phase 2 | withdrawn | Sep 10, 2020 | Virginia Commonwealth University | AbbVie decided to stop trial involving Venetoclax for safety measures needed | Safety / toxicity |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade… | Phase 2 | withdrawn | Apr 3, 2019 | Ochsner Health System | Lack of accrual | Enrollment / accrual |
| NCT03516084 | A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based… | Phase 3 | terminated | May 4, 2018 | Zai Lab (Shanghai) Co., Ltd. | As the treatment model of extensive-stage small cell lung cancer changed rapidly and the enrollment… | Enrollment / accrual |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT03116971 | Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC)… | Phase 1 | terminated | Apr 17, 2017 | EMD Serono Research & Development Institute, Inc. | Enrollment in the study was prematurely terminated due to recruitment challenges and not due to… | Safety / toxicity |
| NCT01859741 | A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum…(PINNACLE) | Phase 1 / Phase 2 | terminated | May 22, 2013 | OncoMed Pharmaceuticals, Inc. | OMP-59R5 did not improve PFS. | Other (stated, no rule matched) |
| NCT03607682 | Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With… | N/A | terminated | Jul 31, 2018 | Vanderbilt-Ingram Cancer Center | PI left institution and loss of funding | Investigator |
| NCT03026166 | A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or… | Phase 1 / Phase 2 | terminated | Jan 20, 2017 | AbbVie | Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2. | Safety / toxicity |
| NCT01803269 | Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating… | Phase 2 | terminated | Mar 4, 2013 | University of Chicago | Due to lack of activity and slow accrual | Enrollment / accrual |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated…(CARACTER) | N/A | terminated | Mar 13, 2013 | Amphia Hospital | bad taste of Caphosol - early stop of intake by patients | Other (stated, no rule matched) |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | Phase 1 | terminated | Apr 26, 2010 | University of Maryland, Baltimore | Toxicity was not felt to be acceptable for further development. | Safety / toxicity |
| NCT02819999 | A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients… | Phase 1 | terminated | Jun 30, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | Phase 2 | terminated | Jul 12, 2011 | Cambridge University Hospitals NHS Foundation Trust | Following DMC review, due to slow recruitment of evaluable patients. | Enrollment / accrual |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | — | terminated | Apr 10, 2012 | Addario Lung Cancer Medical Institute | interim assessment by sponsor | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 4, 2024source: clinicaltrials